Sana Biotechnology, Inc. (SANA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
7 readings, 3 filed under bull and 4 under bear. Every figure is ours; the model chose the side.
the bull case· 3
12
supplier and customer relationships disclosed in SEC filings
sec filingsedgar211
managers reporting a position in thirteen f filings
13fJun 30 '26+8.22%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 4
13
managers whose positions make up four fifths of reported value
13fJun 30 '269 of 21
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '266 of 8
recent reports with moves under the options implied range
earnings historyimplied vs realized0.23%
largest fund weight reported for the State Street SPDR S and P Biotech ETF
n-portJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Nov 9 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
tall tick = annual report · 1 on record
211 managers report a position worth $647.4M between them, and 13 of them hold 80% of it.
SANA (Sana Biotechnology, Inc.) has 12 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: BEAM +0.40%, in healthcare.
Of the 6 companies Sana Biotechnology, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
Sana Biotechnology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 3.16 · gapped above the open, then crossed back over prior close. High/low 3.19 at 4:00 am ET, 3.13 at 5:45 am ET.